Literature DB >> 26812164

Atherosclerosis in Sjögren's syndrome: evidence, possible mechanisms and knowledge gaps.

Valéria Valim1, Eva Gerdts2, Roland Jonsson3, Gilda Aparecida Ferreira4, Karl Albert Brokstad5, Johan G Brun6, Helga Midtbø7, Piotr Mateusz Mydel5.   

Abstract

Inflammation has been associated with higher cardiovascular risk in rheumatic autoimmune diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus. More recently, primary Sjögren's syndrome (pSS) was also demonstrated as an independent risk factor for cardiovascular disease, emerging as a new interesting model to study atherosclerosis in autoimmune diseases. Patients with pSS have a higher prevalence of developing traditional cardiovascular risk factors like hypertension and dyslipidaemia predisposing for endothelial dysfunction and premature atherosclerosis. However, the disease-specific mechanisms for premature atherosclerosis in pSS are not fully understood. The aim of this review was to critically analyse the current literature on cardiovascular risks in pSS and to discuss the traditional and disease-associated risk factors. We also suggest possible new mechanisms that should be explored in future research to close the current knowledge gaps on the association of pSS, premature atherosclerosis, and clinical cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26812164

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  9 in total

Review 1.  Cardiac involvement in primary Sjӧgren's syndrome.

Authors:  Li Qin; Yiwen Zhang; Xiaoqian Yang; Qiang Luo; Han Wang
Journal:  Rheumatol Int       Date:  2021-08-13       Impact factor: 2.631

Review 2.  Subclinical Atherosclerosis in Primary Sjögren's Syndrome: Does Inflammation Matter?

Authors:  Elena Bartoloni; Alessia Alunno; Giacomo Cafaro; Valentina Valentini; Onelia Bistoni; Angelo Francesco Bonifacio; Roberto Gerli
Journal:  Front Immunol       Date:  2019-04-17       Impact factor: 7.561

3.  Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome.

Authors:  J Mofors; M Holmqvist; L Westermark; A Björk; M Kvarnström; H Forsblad-d'Elia; S Magnusson Bucher; P Eriksson; E Theander; T Mandl; M Wahren-Herlenius; G Nordmark
Journal:  J Intern Med       Date:  2019-06-17       Impact factor: 8.989

Review 4.  Role of the eNOS Uncoupling and the Nitric Oxide Metabolic Pathway in the Pathogenesis of Autoimmune Rheumatic Diseases.

Authors:  Anna Łuczak; Marta Madej; Agata Kasprzyk; Adrian Doroszko
Journal:  Oxid Med Cell Longev       Date:  2020-04-13       Impact factor: 6.543

5.  Promoting sustainable physical activity among middle-aged Iranian women: a conceptual model-based interventional study.

Authors:  Mohammad Shariati; Houra Pourrajabali Astaneh; Leila Khedmat; Farnaz Khatami
Journal:  BMC Womens Health       Date:  2021-01-02       Impact factor: 2.809

6.  Lipoprotein-associated phospholipase A2 and carotid intima-media thickness in primary Sjögren syndrome.

Authors:  Selcan Gültuna; Sevinç Can Sandıkçı; Hatice Kaplanoğlu; Fevzi Nuri Aydın; Funda Seher Özalp Ateş
Journal:  Arch Rheumatol       Date:  2021-10-16       Impact factor: 1.007

7.  Sjögren's syndrome.

Authors:  Fiona André; Barbara C Böckle
Journal:  J Dtsch Dermatol Ges       Date:  2022-07-01       Impact factor: 5.231

8.  Cardiovascular Risk and Endothelial Dysfunction in Primary Sjogren Syndrome Is Related to the Disease Activity.

Authors:  Anna Łuczak; Rafał Małecki; Michał Kulus; Marta Madej; Ewa Szahidewicz-Krupska; Adrian Doroszko
Journal:  Nutrients       Date:  2021-06-17       Impact factor: 5.717

9.  Increased risk of aortic aneurysm and dissection in patients with Sjögren's syndrome: a nationwide population-based cohort study in Taiwan.

Authors:  Yi-Da Tsai; Wu-Chien Chien; Shih-Hung Tsai; Chi-Hsiang Chung; Shi-Jye Chu; Sy-Jou Chen; Wen-I Liao; Chih-Jen Yang; Min-Tser Liao; Jen-Chun Wang
Journal:  BMJ Open       Date:  2018-09-21       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.